OptimizeRx (NASDAQ:OPRX) Releases Earnings Results

OptimizeRx (NASDAQ:OPRX) announced its quarterly earnings data on Thursday. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.18, Zacks reports. The firm had revenue of $32.24 million during the quarter, compared to analysts’ expectations of $30.92 million. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%.

Here are the key takeaways from OptimizeRx’s conference call:

• Strong FY2025 results: Q4 revenue was $32.2M and adjusted EBITDA $12M, with full-year revenue $109.4M, adjusted EBITDA $24.3M, Rule of 40 performance, >20% adjusted EBITDA margin, and nearly $19M in operating free cash flow.
• Conservative 2026 guidance: Management lowered 2026 revenue to $109M–$114M and adjusted EBITDA to $21M–$25M, citing softness from a market shift away from managed services and MFN-driven client conservatism that shortened contract durations.
• Capital allocation and balance sheet actions: Year-end cash/short-term investments rose to $23.4M after $8M of debt paydown, the board authorized a $10M share repurchase, and management plans to prioritize debt reduction while opportunistically buying back stock.
• Growth & product momentum: Management highlighted DAAP/DAAP subscription conversion near a ~10% exit run-rate, a 116% net revenue retention rate, expanding wins with mid-tier and med-tech clients, and views AI as a potential tailwind reallocating spend toward execution where OptimizeRx competes.

OptimizeRx Price Performance

NASDAQ OPRX traded down $1.29 during trading on Friday, hitting $6.24. 819,904 shares of the stock traded hands, compared to its average volume of 376,014. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.20. OptimizeRx has a 12-month low of $3.99 and a 12-month high of $22.25. The firm has a 50-day simple moving average of $10.63 and a 200-day simple moving average of $14.80. The company has a market capitalization of $116.31 million, a P/E ratio of 19.67 and a beta of 1.20.

OptimizeRx declared that its Board of Directors has approved a share repurchase plan on Thursday, March 5th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

Several brokerages recently weighed in on OPRX. Citizens Jmp upped their target price on shares of OptimizeRx from $23.00 to $24.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Stifel Nicolaus lowered their price objective on OptimizeRx from $21.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (d+)” rating on shares of OptimizeRx in a research note on Monday, December 22nd. Finally, Stephens lowered their price target on OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating on the stock in a report on Friday. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Quantbot Technologies LP bought a new stake in OptimizeRx in the second quarter worth $44,000. BNP Paribas Financial Markets grew its stake in shares of OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after buying an additional 2,215 shares in the last quarter. ExodusPoint Capital Management LP bought a new stake in shares of OptimizeRx in the 4th quarter worth about $150,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of OptimizeRx in the 4th quarter worth about $158,000. Finally, AQR Capital Management LLC raised its position in shares of OptimizeRx by 18.4% during the 4th quarter. AQR Capital Management LLC now owns 14,514 shares of the company’s stock valued at $178,000 after buying an additional 2,256 shares in the last quarter. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx News Roundup

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 results topped estimates — OPRX reported $0.51 EPS and $32.24M in revenue, beating consensus and highlighting continued revenue growth. This is the fundamental positive underpinning the shares. GlobeNewswire: Press Release
• Positive Sentiment: Board authorized a $10.0M share repurchase (up to ~6.8% of shares), a signal management views the stock as undervalued and a potential support for the share price. RTT News: Buyback
• Neutral Sentiment: Company-hosted earnings call and multiple transcripts are available for investors to assess management commentary and execution plans; useful for judging sustainability of growth and margin outlook. Yahoo Finance: Earnings Highlights
• Neutral Sentiment: Trading experienced repeated LULD pauses (multiple intraday halts) — this indicates elevated volatility and may have contributed to larger intraday moves and volume. (Market notices reported multiple LULD pauses.)
• Negative Sentiment: FY‑2026 revenue guidance of $109M–$114M came in materially below the consensus (~$122M), creating the primary negative catalyst pushing the stock lower as investors reprice forward growth expectations. Seeking Alpha: Guidance
• Negative Sentiment: Stephens cut its price target from $17 to $10 and moved to an “equal weight” rating, sending a clear signal to investors and likely amplifying selling pressure from analysts/quant strategies. Benzinga: Analyst Note

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.